

【雑誌】

No.	発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
1	Yanaba K, Yoshizaki A, Asano Y, Kadono T, <u>Sato S</u>	Serum interleukin-9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis.	J Rheumatol	38(10)	2193-2197	2011
2	Yoshizaki A, Yanaba K, Ogawa A, Iwata Y, Ogawa F, Takenaka M, Shimizu K, Asano Y, Kadono T, <u>Sato S</u>	The specific free radical scavenger edaravone suppresses fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.	Arthritis Rheum	63(10)	3086-3097	2011
3	Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, <u>Sato S</u>	Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.	Arthritis Rheum	63(11)	3575-3585	2011
4	Asano Y, Ihn H, Jinnin M, Tamaki K, <u>Sato S</u>	Altered dynamics of TGF- receptors in scleroderma fibroblasts.	Arthritis Rheum	70(2)	384-387	2011
5	Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, <u>Sato S</u>	Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.	Clin Rheumatol	30(2)	231-237	2011
6	Hasegawa M, Fujimoto M, Hamaguchi Y, Matsushita T, Inoue K, <u>Sato S</u> , Takehara K	Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis.	J Rheumatol	38(5)	877-884	2011
7	Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, <u>Ihn H</u>	Circulating miR-29a levels in patients with scleroderma spectrum disorder.	J Dermatol Sci	61(1)	67-69	2011
8	Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, Igata T, Makino T, Fukushima S, <u>Ihn H</u>	Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC- in normal dermal fibroblasts.	J Invest Dermatol	131(1)	655-661	2011
9	Tochimoto A, <u>Kawaguchi Y</u> , Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H	Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: four-year follow-up.	Mod Rheumatol	21(3)	296-301	2011
10	Hoshino K, Satoh T, Kawaguchi Y, <u>Kuwana M</u>	Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis.	Arthritis Rheum	63(8)	2465-2472	2011
11	Furuya Y, <u>Kuwana M</u>	Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.	J Rheumatol	38(10)	2186-2192	2011
12	Kajii, Suzuki C, Kashiwara J, Kobayashi E, Kubo Y, Miyamoto H, Yuuki T, <u>Yamamoto T</u> , Nakae T	Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.	Clin Exp Immunol	163(2)	235-241	2011
13	Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Muroi E, <u>Ogawa E</u> , Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S	Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation.	Ann Rheum Dis	70(1)	194-200	2011
14	<u>Mugii N</u> , Hasegawa M, Matsushita T, Hamaguchi Y, Horie S, Yahata T, Inoue K, Someya F, Fujimoto M, Takehara K	Association between nail-fold capillary findings and disease activity in dermatomyositis.	Rheumatology	50(6)	1091-1098	2011

15	Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.	J Rheumatol	39(3)	539-544	2012
16	Taniguchi T, Asano Y, Hatano M, Tamaki Z, Tomita M, Kawashima T, Miyazaki M, Sumida H, Akamata K, Takahashi T, Ichimura Y, Toyama T, Sugita M, Noda S, Yao A, Kinugawa K, <u>Sato S</u>	Effects of bosentan on non-digital ulcers in patients with systemic sclerosis.	Br J Dermatol	166(2)	417-421	2012
17	Hasegawa M, <u>Asano Y</u> , Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Sasaki T, Takahashi H, Tanaka S, Takehara K, Sato S.	Investigation of prognostic factors for skin sclerosis and lungfunction in Japanese patients with early systemic prospective observational study.sclerosis: a multicentre.	Rheumatology (Oxford)	51(1)	129-133	2012
18	<u>Kuwana M</u> , Okazaki Y	Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols.	Ann Rheum Dis	71(4)	617-620	2012
19	Hasebe N, Kawasaki A, Ito I, Kawamoto M, Hasegawa M, Fujimoto M, Furukawa H, Tohma S, Sumida T, Takehara K, <u>Sato S</u> , Kawaguchi Y, Tsuchiya N	Association of UBE2L3 polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese population.	Ann Rheum Dis	71(7)	1259-1260	2012
20	Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba K, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.	PLoS One	7(2)	e32272	2012
21	Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Kuwano Y, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.	Br J Dermatol	167(3)	542-547	2012
22	Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba Y, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	Constitutive activation of c-Abl/protein kinase C- β /Fli pathway in dermal fibroblasts derived from patients with localized scleroderma.	Br J Dermatol	167(5)	1098-1105	2012
23	Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u>	Increased accumulation of thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts.	Am J Pathol	180(2)	703-714	2012
24	Honda N, Jinnin M, Kajiwara I, Makino T, Makino K, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u>	TGF- β -mediated down-regulation of microRNA-196a contributes to the constitutive up-regulated type I collagen expression in scleroderma dermal fibroblasts.	J Immunol	188	3323-3331	2012
25	Nakajima T, Jinnin M, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u>	Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts.	J Immunol	188	3573-3583	2012

26	Sing T, Jinnin M, Yamane K, Honda N, Makino K, Kajihara I, Makino T, Sakai K, Mashuguchi S, Fukushima S, <u>Ihn H</u>	microR-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma.	Rheumatology	51	1550-1556	2012
27	Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, <u>Kuwana M</u>	Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort.	Rheumatology	51(10)	1846-1854	2012
28	Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, <u>Fujimoto M</u> , Takehara K	Potential roles of interleukin 17A in the development of skin fibrosis.	Arthritis Rheum	64 (11)	3726-3735	2012
29	Wakatsuki-Nakamura T, Oyama N, <u>Yamamoto T</u>	Local injection of latency-associated peptide (LAP), a linker propeptide specific for active form of transforming growth factor-beta1 (TGF- β 1), inhibits dermal sclerosis in bleomycin-induced murine scleroderma.	Exp Dermatol	21	189-194	2012
30	Takahashi T, Asano Y, Akamata K, Aozasa N, Taniguchi T, Noda S, Masui Y, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	The dynamics of serum angiotensin-2 levels correlates with the efficacy of intravenous cyclophosphamide pulse for interstitial lung disease associated with systemic sclerosis.	Mod Rheumatol	23(5)	884-890	2013
31	Makino K, Jinnin M, Aoi J, Hirano A, Kajihara I, Makino T, Sakai K, Fukushima S, Inoue Y, <u>Ihn H</u>	Dicoidin domain receptor 2 -micro RNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts.	J Invest Dermatol	133(1)	110-119	2013
32	Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Okamoto Y, Hasegawa M, <u>Fujimoto M</u> , <u>Ihn H</u>	microRNA-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin α 3.	Am J Pathol	182(1)	206-216	2013
33	Yamaguchi Y, <u>Kuwana M</u>	Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis.	Histol Histopathol	28(2)	175-183	2013
34	Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, Hasegawa M, Mukaida N, <u>Fujimoto M</u> , Takehara K	Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis.	J Dermatol Sci	69(3)	250-258	2013
35	<u>Hasegawa M</u> , Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K	Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.	Rheumatology	52(2)	242-251	2013
36	Takehara K, <u>Ihn H</u> , <u>Sato S</u>	A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.	Clin Exp Rheumatol	31(2 Suppl 76)	151-156	2013
37	Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T, Ichimura Y, Toyama T, Sumida H, Kuwano Y, Yanaba K, Tada Y, Sugaya M, Kadono T, <u>Sato S</u>	A possible contribution of decreased cathepsin V expression caused by Fli deficiency to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.	Rheumatology	52(5)	790-799	2013
38	Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, <u>Ihn H</u> , Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, <u>Sato S</u> , Takehara K	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study.	Mod Rheumatol	23(6)	1076-1084	2013

39	<u>Asano Y</u> , Trojanowska M	Fli1 represses transcription of the human $\alpha 2(I)$ collagen gene by recruitment of the HDAC1/p300 complex.	PLoS One	8	e74930	2013
40	Masui Y, <u>Asano Y</u> , Shibata S, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba K, Tada Y, Sugaya M, Sato S, Kadono T	A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.	Rheumatology (Oxford)	52	1239-1244	2013
41	Ota Y, <u>Kawaguchi Y</u> , Takagi K, Ichida H, Gono T, Hanaoka M, Higuchi T, Yamanaka H	Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis.	Clin Immunol	147	71-78	2013
42	Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, <u>Kuwana M</u>	Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop.	Arthritis Res Ther	15(4)	R74	2013
43	Seta N, Okazaki Y, Miyazaki H, Kato T, <u>Kuwana M</u>	Platelet-derived stromal cell-derived factor-1 is required for the transformation of circulating monocytes into multipotential cells.	PLoS One	8(9)	e74246	2013
44	Amiya E, Takata M, Watanabe M, Takahashi T, Asano Y, <u>Hatano M</u> , Ozeki A, Watanabe A, Kawarasaki S, Tamaki Z, Taniguchi T, Ichimura Y, Toyama T, Nagai R, Sato S, Komuro I	Presence of desaturated hemoglobin enhances the contribution of blood cells to flow-mediated dilation in subjects with systemic sclerosis.	Int J Cardiol	168(3)	3125-3127	2013
45	Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, <u>Fujimoto M</u>	FTY720 ameliorates murine Scl-cGVHD by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.	Arthritis Rheum	65(6)	1624-1635	2013
46	Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Tedder TF, <u>Fujimoto M</u>	Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.	Blood	121(16)	3274-3283	2013
47	Ueda-Hayakawa I, Hasegawa M, Hamaguchi Y, Takehara K, <u>Fujimoto M</u>	Circulating $\alpha 2(I)$ T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of pro $\alpha 2(I)$ collagen of fibroblasts.	J Dermatol Sci	69(1)	54-60	2013